Novo Nordisk Demerges
Executive Summary
Denmark's Novo Nordisk is demerging, to make its businesses more flexible and fast-footed.
You may also be interested in...
From HCV Partner To Acquirer, BMS Makes $885 M Offer for ZymoGenetics
Ever since its pure-play biopharma strategy went into effect, Bristol-Myers Squibb has preferred buying biotechs it knows well. Hepatitis C development partner ZymoGenetics is no exception.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.